Our advanced AI models are unrivaled in market performance for predicting the risk of kidney function decline. We deliver actionable clinical insights to the point of care.
PulseData uses predictive modeling to identify high-risk patients early, preventing disease progression, improving patient outcomes and reducing costs.
PulseData's ML/AI solution identifies undiagnosed and under-diagnosed patients at risk for chronic conditions and significantly improves HCC accuracy.
Our advanced artificial intelligence models have the highest performance in the market, building on our patented machine learning system for predicting risk.
Identifying the next best care management action and automate delivery of specific care actions directly to the point of care.
% reduction in admissions
$ saved per identified
X CKD Stage 1-2 Identified
"In a perfect world data for KFRE would be available in every clinic/health system. But the perfect world doesn’t exist, not even in neph clinics, let alone health systems. For the real world, PulseData has the best solution on the market by miles."
“PulseData helped us act quickly to build a safety net for all our members and proactively intervene with those most at-risk. We’re excited about the benefits this partnership will bring to our members and primary care practices moving forward.”
"The future of healthcare will depend on leveraging advanced technologies that keep patients healthier and costs lower. PulseData is focused on having exactly this impact on renal disease, a chronic condition that affects millions of patients and costs the healthcare system over $100 billion a year. We're excited to continue our partnership with such a brilliant and mission-driven team of entrepreneurs."
“PulseData has built the best data intelligence platform for predicting the progression of kidney disease.... PulseData’s models equip local care teams to deliver the highest quality care to the most at-risk patient cohorts. We’re excited about the results PulseData has achieved. We look forward to partnering with Teddy, Hai Po and the rest of the management team to improve kidney care for patients.”
“Pain-point targeted technology:…startups focused on solving specific pain points can find success in helping risk takers target niche opportunities. For example PulseData uses AI & ML to understand patient data and predict outcomes for chronic kidney disease and end-stage renal disease. By targeting kidney care, which accounts for roughly 20% of CMS spending, PulseData can potentially provide quick wins to customers. Risk-takers will use these savings to further invest in VBC technology."